PARIS (Thomson Financial) - BioAlliance Pharma SA said it plans to pursue
its strategy of acquisitions in the European oncology and HIV markets, despite
Immtech Pharmaceuticals Inc's recent decision to end a trial of pafuramidine,
for which BioAlliance has the European rights.
The French drug development company said it will continue its "strategy for
the targeted acquisition of complementary products".
tfn.paris@thomson.com
gt/hjp/gt/wj
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|